Outcomes of Pituitary Radiation for Cushing's Disease

Natasha Ironside, Ching Jen Chen, Cheng Chia Lee, Daniel Trifiletti, Mary Lee Vance, Jason P. Sheehan

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Abstract

Achievement of biochemical remission with preservation of normal pituitary function is the goal of treatment for Cushing's disease. For patients with persistent or recurrent Cushing's disease after transsphenoidal resection, radiation therapy may be a safe and effective treatment. Stereotactic radiosurgery is favored over conventional fractionated external beam radiation. Hormonal recurrence rates range from 0% to 36% at 8 years after treatment. Tumor control rates are high. New pituitary hormone deficiency is the most common adverse effect after stereotactic radiosurgery and external beam radiation. The effects of radiation planning optimization and use of adjuvant medication on endocrine remission rates warrant investigation.

Original languageEnglish (US)
Title of host publicationEndocrinology and Metabolism Clinics of North America
EditorsAdriana G. Ioachimescu
PublisherW.B. Saunders
Pages349-365
Number of pages17
Volume47
Edition2
ISBN (Print)9780323612937
DOIs
StatePublished - Jun 1 2018

    Fingerprint

Keywords

  • Cushing's disease
  • Endocrine
  • Radiation therapy
  • Remission
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Ironside, N., Chen, C. J., Lee, C. C., Trifiletti, D., Vance, M. L., & Sheehan, J. P. (2018). Outcomes of Pituitary Radiation for Cushing's Disease. In A. G. Ioachimescu (Ed.), Endocrinology and Metabolism Clinics of North America (2 ed., Vol. 47, pp. 349-365). W.B. Saunders. https://doi.org/10.1016/j.ecl.2018.01.002